Mr. Tyree has served as a member of our Board of Directors since May 2012, as Chairman of our Board from 2014 to 2021, and as our Lead Independent Director since July 2021.
He has a distinguished career in health care operations and M&A spanning more than 30 years. He currently serves as an independent board member for several public and private healthcare companies, including Assertio (NASDAQ: ASRT) since October 2016. He was the former lead independent Director of Chemocentryx (NASDAQ: CCXI), which was sold.
Mr. Tyree previously served as a member of the board of directors of SonarMed, Inc. (now a subsidiary of Medtronic plc). He is the retired Chairman and Co-Founder of Tyree & D’Angelo Partners, a private equity investment firm founded in 2012. He previously held numerous executive positions at Abbott Laboratories Inc., including Executive Vice President Global Pharmaceuticals, Senior Vice President Global Nutrition, and Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development. Prior to joining Abbott, he held leadership positions at Sugen Inc., Bristol-Myers Squibb Inc., and Pfizer Inc. Mr. Tyree is a past chair of the Illinois Biotechnology Industry Organization (iBIO) and council of advisors to develop a new strategic plan for the Illinois Medical District, and has served as a member of the Advisory Board of the University of Chicago Graduate School of Business, and the Chicago Mayor’s Council of Technology Advisors.
Mr. Tyree earned his MBA from the Kelley School of Business at Indiana University, as well as bachelor’s degrees in psychology and forensic studies from Indiana University.
What is James L. Tyree's net worth?
The estimated net worth of James L. Tyree is at least $131.88 thousand as of December 30th, 2024. Mr. Tyree owns 45,791 shares of Genelux stock worth more than $131,878 as of August 27th. This net worth estimate does not reflect any other investments that Mr. Tyree may own. Learn More about James L. Tyree's net worth.
How do I contact James L. Tyree?
Has James L. Tyree been buying or selling shares of Genelux?
James L. Tyree has not been actively trading shares of Genelux during the last quarter. Most recently, James L. Tyree sold 3,460 shares of the business's stock in a transaction on Monday, December 30th. The shares were sold at an average price of $2.46, for a transaction totalling $8,511.60. Following the completion of the sale, the director now directly owns 45,791 shares of the company's stock, valued at $112,645.86. Learn More on James L. Tyree's trading history.
Are insiders buying or selling shares of Genelux?
In the last year, insiders at the sold shares 15 times. They sold a total of 56,111 shares worth more than $199,950.70. The most recent insider tranaction occured on August, 4th when insider Yong Yu sold 653 shares worth more than $1,919.82. Insiders at Genelux own 7.5% of the company.
Learn More about insider trades at Genelux. Information on this page was last updated on 8/4/2026.
